Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) overview
Post-essential thrombocythemia myelofibrosis (post-ET MF) is a rare, chronic blood disorder characterized by the progression of essential thrombocythemia (ET), a type of myeloproliferative neoplasm (MPN), to myelofibrosis (MF). It represents an advanced stage in the continuum of MPNs, involving abnormal production and functioning of blood cells in the bone marrow. Essential thrombocythemia is characterized by the overproduction of platelets (thrombocytes) leading to an increased risk of blood clots. Over time, a subset of individuals with ET may progress to myelofibrosis, a condition where the bone marrow becomes fibrotic (scarred), leading to impaired production of blood cells. The symptoms of post-ET MF can vary widely and include fatigue, weakness, and shortness of breath due to anemia; enlargement of the spleen, leading to abdominal discomfort or pain; bone pain, especially in the ribs and back; easy bruising, bleeding, or prolonged bleeding time due to abnormal platelet function; and night sweats, weight loss, or fever.
For a complete picture of PTSR and LoA scores for drugs in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
